Loading patent…
AssigneeProyecto De Biomedicina Cima, S.L.
InventorsJesus Prieto Valtuena, Ma Pilar Civeira Murillo, Esther Larrea Leoz
Estimating the term…
The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFNα5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.
1-10. (canceled)
A method for treating a patient having a liver disease of viral hepatitis C origin, said method comprising a step of administering to the patient an amount of IFN-alpha 5 or a nucleotide sequence encoding IFN-alpha 5 that is effective to raise the level of IFN-alpha 5 in the patient.
A method according to claim 16, wherein said recombinant protein is prepared by cloning an expression vector in a procaryotic host organism.
A method according to claim 16, wherein said recombinant protein is prepared by cloning an expression vector in E. coli.
A method according to claim 19, wherein the eukaryotic host organism is Solanum tuberosum.
A method comprising screening a patient suspected of having a liver disease, said method comprising assaying liver cells of the patient for reduced levels of IFN-alpha 5.
Dependencies are inferred from the claim text.